Sequoia Financial Advisors LLC Acquires 1,580 Shares of Solventum Co. (NYSE:SOLV)

Sequoia Financial Advisors LLC grew its holdings in shares of Solventum Co. (NYSE:SOLV) by 27.5% during the fourth quarter, Holdings Channel reports. The firm owned 7,317 shares of the company’s stock after purchasing an additional 1,580 shares during the period. Sequoia Financial Advisors LLC’s holdings in Solventum were worth $483,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. New York Life Investment Management LLC grew its holdings in Solventum by 0.7% during the fourth quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock valued at $1,223,000 after purchasing an additional 136 shares during the last quarter. Blue Trust Inc. grew its stake in Solventum by 2.1% in the 4th quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock valued at $549,000 after buying an additional 161 shares during the last quarter. MML Investors Services LLC raised its holdings in Solventum by 3.2% in the 3rd quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock worth $373,000 after acquiring an additional 168 shares during the period. Savant Capital LLC lifted its position in Solventum by 6.3% during the 4th quarter. Savant Capital LLC now owns 3,914 shares of the company’s stock worth $259,000 after acquiring an additional 233 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. boosted its holdings in Solventum by 5.3% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,227 shares of the company’s stock valued at $345,000 after acquiring an additional 261 shares during the period.

Solventum Price Performance

NYSE:SOLV opened at $75.38 on Wednesday. The company has a market capitalization of $13.04 billion and a price-to-earnings ratio of 27.41. The company has a 50-day moving average of $74.77 and a 200-day moving average of $71.38. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Wall Street Analysts Forecast Growth

SOLV has been the topic of a number of recent analyst reports. Wells Fargo & Company lifted their price objective on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Bank of America upped their price target on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, February 26th. The Goldman Sachs Group raised their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. Morgan Stanley upped their target price on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. Finally, Piper Sandler raised their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Solventum has a consensus rating of “Hold” and an average price target of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.